!!Research output per year
!!Research output per year
個人檔案
研究專長
癌症藥物治療學、安寧緩和藥物治療學、藥師執業教育、危害性藥品處理
教育/學術資格
PhD, 藥學, Creighton University
指紋
查看啟用 Shao-Chin Chiang 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
- 1 類似的個人檔案
過去五年中的合作和熱門研究領域
國家/地區層面的近期外部共同作業。按一下圓點深入探索詳細資料，或
-
Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma
Chiang, S. T., Chueh, C. H., Wen, Y. W., Chiang, S. C., Li, W. H. & Tsai, Y. W., 12月 2026, 於: Cost Effectiveness and Resource Allocation. 24, 1, 42.研究成果: Article › 同行評審
開啟存取 -
Impact of same-day ART initiation on medical care and medication discontinuation among patients with incident HIV infection or AIDS in Taiwan: A population-based cohort study
Chueh, C. H., Yu, H. J., Wen, Y. W., Shiu, M. N., Chen, Y. Y., Chiang, S. C. & Tsai, Y. W., 4月 2025, 於: Journal of Infection and Public Health. 18, 4, 102677.研究成果: Article › 同行評審
開啟存取3 引文 斯高帕斯（Scopus） -
Modeling brain metastases in cost effectiveness analysis of atezolizumab for extensive stage small cell lung cancer
Chen, H. L., Chueh, C. H., Huang, W. M., Chan, S. H., Cheng, H. H., Chiang, S. C., Wu, C. E., Wen, Y. W. & Tsai, Y. W., 12月 2025, 於: Scientific reports. 15, 1, 39298.研究成果: Article › 同行評審
開啟存取3 引文 斯高帕斯（Scopus） -
Validation of Risk Models for Predicting Febrile Neutropenia Among Breast Cancer Patients Receiving Chemotherapy: A Real-World Study
Hsu, S. W., Chiang, S. C., Hsu, J. C. & Ko, Y., 2月 2025, 於: Clinical Therapeutics. 47, 2, p. e1-e4研究成果: Article › 同行評審
1 引文 斯高帕斯（Scopus） -
Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan
Tseng, T. H., Chiang, S. C., Hsu, J. C. & Ko, Y., 6月 2024, 於: PLoS ONE. 19, 6 June, e0303294.研究成果: Article › 同行評審
開啟存取3 引文 斯高帕斯（Scopus）